학술논문
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
Document Type
Article
Author
Source
In European Journal of Cancer April 2024 201
Subject
Language
ISSN
0959-8049